Fig. 1From: Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation statusWaterfall plot of response to neoadjuvant treatment. Abbreviations: GC, gemcitabine/carboplatin; E, erlotinib. Note: The response rate of one case in the GC arm was not availableBack to article page